The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More People Than Previously Believed Have Schizophrenia.

2.

Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.

3.

Increased detection of adenomas may reduce colon cancer risk after colonoscopy in FIT-based screening.

4.

Including Bereavement in the Care Continuum.

5.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot